Jim Cramer gave top insight on ImmunityBio, Inc. (NYSE:IBRX), sharing a game plan of what to buy, sell, and hold right now. When a caller mentioned that they have a small position in the stock, Cramer ...

According to the FDA, ImmunityBio’s communications “create a misleading impression” that Anktiva can cure or prevent cancer ...

On this news, the price of ImmunityBio’s shares fell $1.98 per share, or 21%, to close at $7.42 per share on March 24, 2026.

The young biopharma outfit's growth potential continues to expand.

The FDA this month issued a warning letter to ImmunityBio regarding promotional statements about cancer drug Anktiva that the ...

By Siddhi Mahatole March 24 (Reuters) - Shares of ImmunityBio fell 26% on Tuesday after the U.S. Food and Drug Administration ...

IF YOU SUFFERED A LOSS ON YOUR IMMUNITYBIO INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS UNDER THE FEDERAL SECURITIES LAWS.

Ten stocks soared by double digits on Tuesday, outperforming Wall Street, as investors took heart from a flurry of corporate ...

As the legal process unfolds, ImmunityBio continues to advance its clinical programs. The company has secured the first Asian approval for Anktiva in Macau. Furthermore, the therapy has been included ...

ImmunityBio Inc. and its billionaire executive chairman Patrick Soon-Shiong overhyped its bladder cancer drug on former White ...

Kirby McInerney LLP reminds investors who purchased ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ:IBRX) securities to contact Lauren Molinaro of Kirby McInerney ...

ImmunityBio Inc. shares are down during Thursday’s premarket session. Year to date, the stock has jumped over 300%. The ...